Key result
ABT-627 prevented further increases in mean arterial pressure in AngII-high salt hypertensive rats without ameliorating renal injury.
Why the study?
Does intervention with ETA or ETB receptor antagonists reduce blood pressure and renal injury in rats with established AngII and high-salt diet-induced hypertension?
Does intervention with ETA or ETB receptor antagonists reduce blood pressure and renal injury in rats with established AngII and high-salt diet-induced hypertension?
Answers are grounded in this paper and cite their sources.
ETA receptor signaling is important in maintaining AngII-HS hypertension, while ETB receptor blockade may be ineffective or counterproductive.
Endothelin (ET) receptor antagonists are antihypertensive and renoprotective in angiotensin II (AngII)-induced hypertension if administered when AngII infusion commences, but their effects on established hypertension are poorly understood. We therefore tested the effects of intervening with an ETA (ABT-627) or ETB (A-192621) receptor antagonist after establishing hypertension with AngII (65 ng/min s.c.) plus 8% NaCl diet (AngII-HS) in rats. Prior to administration of ABT-627, AngII-HS and AngII-HS plus ABT-627 groups displayed robust hypertension (mean arterial pressure (MAP), 170 +/- 5 and 165 +/- 5 mm Hg versus 110 +/- 3 mm Hg in normal salt control rats at day 7, P < 0.05). Administering ABT-627 from day 8 of AngII-HS treatment prevented further rises in MAP (168 +/- 5 and 191 +/- 3 mm Hg at day 13 in AngII-HS plus ABT-627 and AngII-HS, P < 0.001), without blunting the significant increases in urinary protein (19-fold), albumin (25-fold), or MCP-1 excretion (6- to 8-fold) or the reduction in creatinine clearance. Administering A-192621 from day 8 mildly exacerbated AngII-HS induced hypertension (P < 0.05 for AngII-HS versus AngII-HS plus A-192621 on days 11 and 12 only) and reduced plasma nitrite/nitrate concentration (P < 0.05), without affecting proteinuria, albuminuria, or creatinine clearance. These results confirm the importance of ETA receptor signaling in maintaining AngII-HS hypertension and suggest that including ETB receptor blockade in therapeutic approaches to treating hypertension would be ineffective or even counterproductive.
No takes yet. Share an insight, caveat, or question.
Boesen et al. (2010) studied Angiotensin II and high-salt diet-induced hypertension. ABT-627 (ETA receptor antagonist) or A-192621 (ETB receptor antagonist) vs. AngII plus high-salt diet alone (untreated hypertension control) and normal salt vehicle control was evaluated on Mean arterial pressure (MAP) at day 13 (mm Hg) (MD -23 mm Hg, p=<0.001). ABT-627 prevented further increases in mean arterial pressure in AngII-high salt hypertensive rats without ameliorating renal injury.
Synapse has enriched 10 related papers. Consider them for comparative context: